Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699679 | Clinical Oncology | 2008 | 5 Pages |
Abstract
The combination of vinorelbine and infusional 5-FU is active in metastatic breast cancer, including in patients previously treated with an anthracycline and a taxane. Toxicity is generally manageable, but myelosuppression is significant at this dose regimen. Recommended doses for routine clinical use are 5-FU 200Â mg/m2/day and intravenous vinorelbine 30Â mg/m2 days 1 and 15 on a 28-day cycle.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
N.S.A. Stuart, M.B. McIllmurray, J.L. Bishop, S.R.D. Johnston, C.G.A. Price, S.M. O'Reilly, J.K. Joffe, F. Neave, E.C. Whipp,